

LIVE WEBINAR

Tuesday, September 21, 2021 • 12:00 PM ET/9:00 AM PT

Register now

Drug Monitoring Webinar: Presumptive vs Definitive Drug Testing: What Are We Missing?

Presented by Dr Jack Kain and Dr Les Edinboro, moderated by Dr Jeff Gudin

The objectives of this webinar include:

- Learn why, now more than ever, drug testing needs to be incorporated into the standard of clinical care when prescribing controlled substances and assessing patients for medication adherence or drug misuse
- Gain a deeper understanding of the differences between presumptive and definitive drug testing
- Hear results from a recent Quest Diagnostics study using national data, which demonstrate some of the risks of relying solely on point-of-care presumptive testing as a drug monitoring solution

Presented by:



Jack Kain,
PharmD

Director,
Medical Science Liaison,
Quest Diagnostics

Jack Kain, PharmD, has served as a consultant, clinical toxicologist, and medical science liaison for multiple toxicology laboratories. He currently works alongside the Quest Clinical Drug Monitoring & Toxicology team. He earned his PharmD from Lake Erie College of Osteopathic Medicine. His postgraduate training includes a fellowship in forensic toxicology and further graduate coursework in general toxicology. Dr Kain has developed solutions that identify drug-drug interactions and incorporate drug-drug interaction analytics into drug testing platforms. He also provides toxicology and clinical drug testing education for team members and stakeholders addressing the drug misuse epidemic across the nation.



Les Edinboro,
PhD

Executive Science Director,
Toxicology,
Quest Diagnostics

Les Edinboro, PhD, received his BS in chemistry from Gannon University, MS in pharmacology and toxicology from West Virginia University, and PhD in pathology with a focus in forensic and clinical toxicology at Virginia Commonwealth University. He has worked in the field of toxicology for over 35 years and is a fellow of the American Board of Forensic Toxicology. Dr Edinboro currently serves as the executive science director for Toxicology at Quest. He is responsible for the research and development of new toxicology methods, client interfacing, optimization of the Quest toxicology network for clinical drug testing, and clinical and forensic toxicology analysis.

Moderated by:



Jeff Gudin,
MD

Senior Medical Advisor,
Drug Monitoring and Toxicology,
Quest Diagnostics

Jeff Gudin, MD, is a senior medical advisor to the Quest Drug Monitoring division and faculty member at the University of Miami Miller School of Medicine in the Department of Anesthesiology, Perioperative Medicine and Pain Management. He completed his residency in anesthesiology at the Yale University School of Medicine and his fellowship at the Yale Center for Pain Management. Dr Gudin remains active in teaching, patient care, and research, and has lectured internationally on a variety of topics in drug monitoring, pain management, and addiction medicine.

To register for this live webinar, please [click here](#).

Please note: Advance registration is required for participation.

For more information, contact your Quest representative or email EducationalEvents@QuestDiagnostics.com.

Visit Education.QuestDiagnostics.com to view on-demand webinars.

Contact us:

Quest Diagnostics • 500 Plaza Drive • Secaucus, New Jersey 07094 • Attention: Medical Marketing



ONE intermediate contact hour toward ASCLS P.A.C.E.® credit will be available to participating laboratory professionals who attend the webinar and complete the post evaluation.

Quest Diagnostics is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® program.

Quest, Quest Diagnostics, the associated logo and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics.

©2021 Quest Diagnostics Incorporated. All rights reserved. MI10464 8/2021

This communication is intended for healthcare professionals in the USA.

[Unsubscribe from updates.](#)